{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:43:13Z","timestamp":1792788193249,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Key R&D Program of Zhejiang","award":["2024C03162"],"award-info":[{"award-number":["2024C03162"]}]},{"name":"National Natural Science Foundation of China","id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Natural Science Foundation of Zhejiang Province"},{"name":"Pujiang Talents Program"},{"name":"National Key Research and Development Program of China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"DOI":"10.1186\/s40164-026-00830-z","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:32:28Z","timestamp":1788777148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CD84 expression stratifies venetoclax response and reveals a targetable vulnerability in resistant acute myeloid leukemia"],"prefix":"10.1186","volume":"15","author":[{"given":"Xuemei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huafeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"issue":"7","key":"830_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"issue":"4","key":"830_CR2","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/bjh.19314","volume":"204","author":"B Nachmias","year":"2024","unstructured":"Nachmias B, Aumann S, Haran A, Schimmer AD. Venetoclax resistance in acute myeloid leukaemia-Clinical and biological insights. Br J Haematol. 2024;204(4):1146\u201358.","journal-title":"Br J Haematol"},{"issue":"13","key":"830_CR3","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1182\/bloodadvances.2024012906","volume":"8","author":"A Dolnikova","year":"2024","unstructured":"Dolnikova A, Kazantsev D, Klanova M, Pokorna E, Sovilj D, Kelemen CD, et al. Blockage of BCL-XL overcomes venetoclax resistance across BCL2\u2009+\u2009lymphoid malignancies irrespective of BIM status. Blood Adv. 2024;8(13):3532\u201343.","journal-title":"Blood Adv"},{"issue":"1","key":"830_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","volume":"7","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, et al. Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther. 2022;7(1):51.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"830_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40164-022-00283-0","volume":"11","author":"Y Xu","year":"2022","unstructured":"Xu Y, Ye H. Progress in understanding the mechanisms of resistance to BCL-2 inhibitors. Exp Hematol Oncol. 2022;11(1):31.","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"830_CR6","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, et al. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. Cancer Discov. 2020;10(4):536\u201351.","journal-title":"Cancer Discov"},{"issue":"11","key":"830_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI176818","volume":"135","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Murtadha M, Liu M, Caserta E, Napolitano O, Nguyen LXT, et al. Identification of CD84 as a potent survival factor in acute myeloid leukemia. J Clin Invest. 2025;135(11):1.","journal-title":"J Clin Invest"},{"issue":"6","key":"830_CR8","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P Van Galen","year":"2019","unstructured":"Van Galen P, Hovestadt V, Wadsworth Ii MH, Hughes TK, Griffin GK, Battaglia S, et al. Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. Cell. 2019;176(6):1265\u2013e8124.","journal-title":"Cell"},{"key":"830_CR9","doi-asserted-by":"publisher","first-page":"217853","DOI":"10.1016\/j.canlet.2025.217853","volume":"628","author":"H Lu","year":"2025","unstructured":"Lu H, Wang H, Wang Q, Huang D, Han Y, Wang H, et al. Dynamic evolution of venetoclax resistance in acute myeloid leukemia unveiled by longitudinal single-cell RNA-seq. Cancer Lett. 2025;628:217853.","journal-title":"Cancer Lett"},{"issue":"8","key":"830_CR10","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/onc.2013.31","volume":"33","author":"I Binsky-Ehrenreich","year":"2014","unstructured":"Binsky-Ehrenreich I, Marom A, Sobotta MC, Shvidel L, Berrebi A, Hazan-Halevy I, et al. CD84 is a survival receptor for CLL cells. Oncogene. 2014;33(8):1006\u201316.","journal-title":"Oncogene"},{"issue":"6","key":"830_CR11","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.ccell.2020.10.010","volume":"38","author":"S Bhatt","year":"2020","unstructured":"Bhatt S, Pioso MS, Olesinski EA, Yilma B, Ryan JA, Mashaka T, et al. Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Cell. 2020;38(6):872\u201390. e6.","journal-title":"Cancer Cell"},{"issue":"7","key":"830_CR12","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1182\/blood.2024025690","volume":"145","author":"R Nair","year":"2025","unstructured":"Nair R, Vu AH, Freer AK, Bhatia KS, Wang D, Savani MR, et al. Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis. Blood. 2025;145(7):732\u201347.","journal-title":"Blood"},{"issue":"11","key":"830_CR13","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1158\/0008-5472.CAN-17-3024","volume":"78","author":"M Rahmani","year":"2018","unstructured":"Rahmani M, Nkwocha J, Hawkins E, Pei X, Parker RE, Kmieciak M, et al. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells. Cancer Res. 2018;78(11):3075\u201386.","journal-title":"Cancer Res"},{"issue":"1","key":"830_CR14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.14336\/AD.2019.0320","volume":"11","author":"W Sun","year":"2020","unstructured":"Sun W, Wang Y, Zheng Y, Quan N. The Emerging Role of Sestrin2 in Cell Metabolism, and Cardiovascular and Age-Related Diseases. Aging Dis. 2020;11(1):154\u201363.","journal-title":"Aging Dis"},{"issue":"1","key":"830_CR15","doi-asserted-by":"publisher","first-page":"22538","DOI":"10.1038\/srep22538","volume":"6","author":"B Ding","year":"2016","unstructured":"Ding B, Parmigiani A, Divakaruni AS, Archer K, Murphy AN, Budanov AV. Sestrin2 is induced by glucose starvation via the unfolded protein response and protects cells from non-canonical necroptotic cell death. Sci Rep. 2016;6(1):22538.","journal-title":"Sci Rep"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00830-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00830-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00830-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:16:52Z","timestamp":1789993012000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40164-026-00830-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["830"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00830-z","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"12 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Primary AML samples were obtained from patients from diagnostic bone marrow aspirations at the First Affiliated Hospital, Zhejiang University School of Medicine and healthy samples were collected from healthy donor volunteers. Mononuclear cells were isolated by Ficoll density gradient centrifugation for subsequent analysis. Clinical characteristics of all participants are summarized in Supplemental Table\u00a0S1. Sample collection and use were approved by the Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine, and written informed consent was obtained from all participants in accordance with the Declaration of Helsinki. All\n                      in vivo\n                      experiments involving animals in this research followed the ethical standards established by the Institutional Animal Care and Use Committee of Tongji University.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"90"}}